2011
DOI: 10.1177/1538574411418127
|View full text |Cite
|
Sign up to set email alerts
|

Estrogen Replacement Attenuates Exaggerated Neointimal Hyperplasia Following Carotid Endarterectomy in Rats

Abstract: Estradiol treatment in this ovariectomized hyperhomocysteinemia carotid endarterectomy and resultant attenuation of homocysteine and neointima may have relevance to the beneficial effects of estrogen on hyperplastic response.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2013
2013
2013
2013

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 36 publications
0
1
0
Order By: Relevance
“…NO-based therapies have been recommended to take place among pharmacological approaches in the vascular surgery due to their potential clinical effects on neointimal hyperplasia formation. 14) Agents or mechanisms, of which potential effects on neointimal hyperplasia are being investigated, include Nutlin-3, a non-genotoxic activator of the p53 pathway, 16) cinaciguat, the novel soluble guanylate cyclase activator, 17) gene therapy, 18) trichostatin A, a histone deacetylase inhibitor, 19) estrogen, 20) and abciximab, a monoclonal antibody raised against alpha IIb Beta3 integrin. 21) PDE inhibitors as well are among the agents that are being investigated.…”
Section: Discussionmentioning
confidence: 99%
“…NO-based therapies have been recommended to take place among pharmacological approaches in the vascular surgery due to their potential clinical effects on neointimal hyperplasia formation. 14) Agents or mechanisms, of which potential effects on neointimal hyperplasia are being investigated, include Nutlin-3, a non-genotoxic activator of the p53 pathway, 16) cinaciguat, the novel soluble guanylate cyclase activator, 17) gene therapy, 18) trichostatin A, a histone deacetylase inhibitor, 19) estrogen, 20) and abciximab, a monoclonal antibody raised against alpha IIb Beta3 integrin. 21) PDE inhibitors as well are among the agents that are being investigated.…”
Section: Discussionmentioning
confidence: 99%